Skip to main content
Erschienen in: European Radiology 8/2019

09.11.2018 | Musculoskeletal

Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences

verfasst von: Ahmed Larbi, Patrick Omoumi, Vassiliki Pasoglou, Nicolas Michoux, Perrine Triqueneaux, Bertrand Tombal, Catherine Cyteval, Frédéric E. Lecouvet

Erschienen in: European Radiology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the diagnostic accuracy of whole-body T1, short tau inversion recovery (STIR), high b-value diffusion-weighted imaging (DWI), and sequence combinations to detect bone involvement in prostate cancer (PCa) and multiple myeloma (MM) patients.

Materials and methods

We included 50 consecutive patients with PCa at high risk for metastasis and 47 consecutive patients with a histologically confirmed diagnosis of MM who received whole-body MRI at two institutions from January to December 2015. Coronal T1, STIR, and reconstructed coronal high b-values DWI were obtained for all patients. Two musculoskeletal radiologists read individual sequences, pairs of sequences (T1-DWI, T1-STIR, and STIR-DWI), and all combined (T1-STIR-DWI) to detect bone involvement. Receiver operating characteristic curve analysis was used to assess diagnostic performance according to a “best valuable comparator” combining baseline and 6-month imaging and clinical and biological data. Interobserver agreement was calculated.

Results

Interobserver agreement for individual and combined MRI sequences was very good in the PCa group and ranged from good to very good in the MM group (0.76–1.00). In PCa patients, T1-DWI, T1-STIR, and T1-STIR-DWI showed the highest performance (sensitivity = 100% [95% CI = 90.5–100%], specificity = 100% [75.3–100%]). In MM patients, the highest performance was achieved by T1-STIR-DWI (sensitivity = 100% [88.4–100%], specificity = 94.1% [71.3–100%]). T1-STIR-DWI significantly outperformed all sequences (p < 0.05) except T1-DWI (p = 0.49).

Conclusion

In PCa patients, a combination of either T1-DWI or T1-STIR sequences is not inferior to a combination of three sequences to detect bone metastases. In MM, T1-STIR-DWI and T1-DWI had the highest diagnostic performance for detecting bone involvement.

Key Points

• The sequences used in Whole Body MRI studies to detect bone involvement in prostate cancer and myeloma were evaluated.
• In prostate cancer, any pairwise combinations of T1, STIR, and DWI have high diagnostic value.
• In myeloma, the combinations T1-STIR-DWI or T1-DWI sequences should be used.
Literatur
1.
Zurück zum Zitat Heusner TA, Kuemmel S, Koeninger A et al (2010) Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 37:1077–1086CrossRefPubMed Heusner TA, Kuemmel S, Koeninger A et al (2010) Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 37:1077–1086CrossRefPubMed
2.
Zurück zum Zitat Walker R, Kessar P, Blanchard R et al (2000) Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 11:343–350CrossRefPubMed Walker R, Kessar P, Blanchard R et al (2000) Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 11:343–350CrossRefPubMed
3.
Zurück zum Zitat Kwee TC, Fijnheer R, Ludwig I et al (2010) Whole-body magnetic resonance imaging, including diffusion-weighted imaging, for diagnosing bone marrow involvement in malignant lymphoma. Br J Haematol 149:628–630CrossRefPubMed Kwee TC, Fijnheer R, Ludwig I et al (2010) Whole-body magnetic resonance imaging, including diffusion-weighted imaging, for diagnosing bone marrow involvement in malignant lymphoma. Br J Haematol 149:628–630CrossRefPubMed
5.
Zurück zum Zitat Dimopoulos MA, Hillengass J, Usmani S et al (2015) Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 33:657–664CrossRefPubMed Dimopoulos MA, Hillengass J, Usmani S et al (2015) Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 33:657–664CrossRefPubMed
6.
Zurück zum Zitat Lee SY, Kim HJ, Shin YR, Park HJ, Lee YG, Oh SJ (2017) Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis. Eur Radiol 27:2333–2347CrossRefPubMed Lee SY, Kim HJ, Shin YR, Park HJ, Lee YG, Oh SJ (2017) Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis. Eur Radiol 27:2333–2347CrossRefPubMed
7.
Zurück zum Zitat Padhani AR, Koh DM, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261:700–718CrossRefPubMed Padhani AR, Koh DM, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261:700–718CrossRefPubMed
8.
Zurück zum Zitat Wu LM, Gu HY, Zheng J et al (2011) Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis. J Magn Reson Imaging 34:128–135CrossRefPubMed Wu LM, Gu HY, Zheng J et al (2011) Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis. J Magn Reson Imaging 34:128–135CrossRefPubMed
9.
Zurück zum Zitat Lauenstein TC, Goehde SC, Herborn CU et al (2004) Whole-body MR imaging: evaluation of patients for metastases. Radiology 233:139–148CrossRefPubMed Lauenstein TC, Goehde SC, Herborn CU et al (2004) Whole-body MR imaging: evaluation of patients for metastases. Radiology 233:139–148CrossRefPubMed
10.
Zurück zum Zitat Lecouvet FE (2016) Whole-body MR imaging: musculoskeletal applications. Radiology 279:345–365CrossRefPubMed Lecouvet FE (2016) Whole-body MR imaging: musculoskeletal applications. Radiology 279:345–365CrossRefPubMed
11.
Zurück zum Zitat Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate Cancer. Eur Urol 71:81–92CrossRefPubMedPubMedCentral Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate Cancer. Eur Urol 71:81–92CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Pasoglou V, Michoux N, Tombal B, Jamar F, Lecouvet FE (2015) wbMRI to detect bone metastases: critical review on diagnostic accuracy and comparison to other imaging modalities. Clin Transl Imaging 3:141–157CrossRef Pasoglou V, Michoux N, Tombal B, Jamar F, Lecouvet FE (2015) wbMRI to detect bone metastases: critical review on diagnostic accuracy and comparison to other imaging modalities. Clin Transl Imaging 3:141–157CrossRef
13.
Zurück zum Zitat Eustace S, Tello R, DeCarvalho V et al (1997) A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol 169:1655–1661CrossRefPubMed Eustace S, Tello R, DeCarvalho V et al (1997) A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol 169:1655–1661CrossRefPubMed
14.
Zurück zum Zitat Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75CrossRefPubMed Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75CrossRefPubMed
15.
Zurück zum Zitat Daldrup-Link HE, Franzius C, Link TM et al (2001) Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 177:229–236CrossRefPubMed Daldrup-Link HE, Franzius C, Link TM et al (2001) Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 177:229–236CrossRefPubMed
16.
Zurück zum Zitat Takenaka D, Ohno Y, Matsumoto K et al (2009) Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 30:298–308CrossRefPubMed Takenaka D, Ohno Y, Matsumoto K et al (2009) Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 30:298–308CrossRefPubMed
17.
Zurück zum Zitat Ohno Y, Koyama H, Onishi Y et al (2008) Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248:643–654CrossRefPubMed Ohno Y, Koyama H, Onishi Y et al (2008) Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248:643–654CrossRefPubMed
18.
Zurück zum Zitat Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA (2004) Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 14:99–105CrossRefPubMed Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA (2004) Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 14:99–105CrossRefPubMed
19.
Zurück zum Zitat Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275–282PubMed Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275–282PubMed
20.
Zurück zum Zitat Pearce T, Philip S, Brown J, Koh DM, Burn PR (2012) Bone metastases from prostate, breast and multiple myeloma: differences in lesion conspicuity at short-tau inversion recovery and diffusion-weighted MRI. Br J Radiol 85:1102–1106CrossRefPubMedPubMedCentral Pearce T, Philip S, Brown J, Koh DM, Burn PR (2012) Bone metastases from prostate, breast and multiple myeloma: differences in lesion conspicuity at short-tau inversion recovery and diffusion-weighted MRI. Br J Radiol 85:1102–1106CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Han SN, Amant F, Michielsen K et al (2018) Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study. Eur Radiol 28:1862–1874CrossRefPubMed Han SN, Amant F, Michielsen K et al (2018) Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study. Eur Radiol 28:1862–1874CrossRefPubMed
22.
Zurück zum Zitat Shen G, Deng H, Hu S, Jia Z (2014) Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 43:1503–1513CrossRefPubMed Shen G, Deng H, Hu S, Jia Z (2014) Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 43:1503–1513CrossRefPubMed
24.
Zurück zum Zitat Messiou C, Collins DJ, Morgan VA, Desouza NM (2011) Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 21:1713–1718CrossRefPubMed Messiou C, Collins DJ, Morgan VA, Desouza NM (2011) Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 21:1713–1718CrossRefPubMed
25.
Zurück zum Zitat Tombal B, Alcaraz A, James N, Valdagni R, Irani J (2014) Can we improve the definition of high-risk, hormone naive, non-metastatic prostate cancer? BJU Int 113:189–199CrossRefPubMed Tombal B, Alcaraz A, James N, Valdagni R, Irani J (2014) Can we improve the definition of high-risk, hormone naive, non-metastatic prostate cancer? BJU Int 113:189–199CrossRefPubMed
26.
Zurück zum Zitat Lecouvet FE, Geukens D, Stainier A et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281–3287CrossRefPubMed Lecouvet FE, Geukens D, Stainier A et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281–3287CrossRefPubMed
27.
Zurück zum Zitat Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137CrossRefPubMed Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137CrossRefPubMed
28.
29.
Zurück zum Zitat Baur-Melnyk A, Buhmann S, Durr HR, Reiser M (2005) Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 55:56–63CrossRefPubMed Baur-Melnyk A, Buhmann S, Durr HR, Reiser M (2005) Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 55:56–63CrossRefPubMed
30.
Zurück zum Zitat Padhani AR, Koh DM (2011) Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 19:181–209CrossRefPubMed Padhani AR, Koh DM (2011) Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 19:181–209CrossRefPubMed
31.
Zurück zum Zitat Koh DM, Blackledge M, Padhani AR et al (2012) Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol 199:252–262CrossRefPubMed Koh DM, Blackledge M, Padhani AR et al (2012) Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol 199:252–262CrossRefPubMed
32.
Zurück zum Zitat Lecouvet FE, Simon M, Tombal B, Jamart J, Vande Berg BC, Simoni P (2010) Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). Eur Radiol 20:2973–2982CrossRefPubMed Lecouvet FE, Simon M, Tombal B, Jamart J, Vande Berg BC, Simoni P (2010) Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). Eur Radiol 20:2973–2982CrossRefPubMed
33.
Zurück zum Zitat Libshitz HI, Malthouse SR, Cunningham D, MacVicar AD, Husband JE (1992) Multiple myeloma: appearance at MR imaging. Radiology 182:833–837CrossRefPubMed Libshitz HI, Malthouse SR, Cunningham D, MacVicar AD, Husband JE (1992) Multiple myeloma: appearance at MR imaging. Radiology 182:833–837CrossRefPubMed
34.
Zurück zum Zitat Moulopoulos LA, Varma DG, Dimopoulos MA et al (1992) Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 185:833–840CrossRefPubMed Moulopoulos LA, Varma DG, Dimopoulos MA et al (1992) Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 185:833–840CrossRefPubMed
36.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed
37.
Zurück zum Zitat DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845CrossRefPubMed DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845CrossRefPubMed
38.
Zurück zum Zitat Lecouvet FE, Vande Berg BC, Malghem J, Omoumi P, Simoni P (2009) Diffusion-weighted MR imaging: adjunct or alternative to T1-weighted MR imaging for prostate carcinoma bone metastases? Radiology 252:624CrossRefPubMed Lecouvet FE, Vande Berg BC, Malghem J, Omoumi P, Simoni P (2009) Diffusion-weighted MR imaging: adjunct or alternative to T1-weighted MR imaging for prostate carcinoma bone metastases? Radiology 252:624CrossRefPubMed
39.
Zurück zum Zitat Latifoltojar A, Hall-Craggs M, Bainbridge A et al (2017) Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. Eur Radiol 27:5325–5336CrossRefPubMedPubMedCentral Latifoltojar A, Hall-Craggs M, Bainbridge A et al (2017) Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. Eur Radiol 27:5325–5336CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Winfield JM, Poillucci G, Blackledge MD et al (2018) Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. Eur Radiol 28:1687–1691CrossRefPubMed Winfield JM, Poillucci G, Blackledge MD et al (2018) Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. Eur Radiol 28:1687–1691CrossRefPubMed
41.
Zurück zum Zitat Park SY, Shin SJ, Jung DC et al (2017) PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer. Eur Radiol 27:2776–2783CrossRefPubMed Park SY, Shin SJ, Jung DC et al (2017) PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer. Eur Radiol 27:2776–2783CrossRefPubMed
42.
Metadaten
Titel
Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences
verfasst von
Ahmed Larbi
Patrick Omoumi
Vassiliki Pasoglou
Nicolas Michoux
Perrine Triqueneaux
Bertrand Tombal
Catherine Cyteval
Frédéric E. Lecouvet
Publikationsdatum
09.11.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 8/2019
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-018-5796-1

Weitere Artikel der Ausgabe 8/2019

European Radiology 8/2019 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.